

## RWANDA

### Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme

<b>1. Country:</b>	Rwanda						
<b>2. Vaccine grant number:</b>	12-RWA-08a-Y, 1215-RWA-13A-X, 1617-RWA-13a-X, 17-RWA-13b-X, 18-RWA-13b-X, 1921-RWA-13b-X						
<b>3. Date of Decision Letter:</b>	30 September 2019						
<b>4. Date of the Partnership Framework Agreement:</b>	7 June 2013						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Rotavirus, Routine						
<b>6. Vaccine type:</b>	Rotavirus						
<b>7. Requested product presentation and formulation of vaccine:</b>	RV1, 1 dose/plastic tube, liq						
<b>8. Programme Duration:<sup>1</sup></b>	2012-2021						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2012-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	27,757,234	1,368,000	-	-	-	-	29,125,234
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2012	12-RWA-08a-Y					126,500
	<b>Disbursement</b>						
	<b>Disbursement date</b>						<b>Amount (US\$)</b>
	30 January, 2012						126,500
<b>11. Product switch grant</b>	Not applicable						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2012-2019</b>	<b>2020</b>					<b>2021</b>
Number of vaccine doses		582,300					-

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Annual Amounts (US\$)	27,757,234	1,368,000	-																																										
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																																												
<b>14. Self-procurement:</b>	Not applicable																																												
<b>15. Co-financing obligations:</b>	<p>According to the co-financing policy, the Country falls within the group: Initial self-financing</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>55,500</td> <td>66,000</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of AD syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of safety boxes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>124,556</td> <td>149,440</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>128,000</td> <td>153,500</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024	Number of vaccine doses	55,500	66,000	-	-	-	Number of AD syringes	-	-	-	-	-	Number of re-constitution syringes	-	-	-	-	-	Number of safety boxes	-	-	-	-	-	Value of vaccine doses (US\$)	124,556	149,440	-	-	-	Total co-financing payments (US\$) (including freight)	128,000	153,500	-	-	-
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024																																								
Number of vaccine doses	55,500	66,000	-	-	-																																								
Number of AD syringes	-	-	-	-	-																																								
Number of re-constitution syringes	-	-	-	-	-																																								
Number of safety boxes	-	-	-	-	-																																								
Value of vaccine doses (US\$)	124,556	149,440	-	-	-																																								
Total co-financing payments (US\$) (including freight)	128,000	153,500	-	-	-																																								
<b>16. Operational support for campaigns:</b>	Not applicable																																												
<b>17. Additional Reporting Requirements:</b>	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul> </td> <td> 31 March 2020  15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																				
	Due dates																																												
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	31 March 2020 15 May 2020																																												
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																												
<b>18. Financial clarifications:</b>	Not applicable																																												
<p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>																																													

**19. Other conditions:**

Not applicable

Signed by

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

30 September 2019